Malek Daniela, Kääb-Sanyal Vanessa
Kooperationsgemeinschaft Mammographie, Berlin, Germany.
Breast Care (Basel). 2016 Jun;11(3):183-7. doi: 10.1159/000446359. Epub 2016 Jun 23.
The German Mammography Screening Program (German MSP) is population-based and intended for women aged 50-69 years (approximately 10.5 million). The program started in 2005 and was implemented within 5 years. This article describes the implementation, structure, and screening process, and presents the results of initial examinations for the prevalence phase.
Data were collected annually from invitation centers (invitation, attendance), screening units (performance, outcomes), and cancer registries (incidence).
In 2009, 92% of all annually eligible women were invited; 50% of the annually eligible population participated. The total cancer detection rate in the period of 2005-2009 was 8.1/1,000; the corresponding recall rate was 5.9%. 19.6% of detected cancers were ductal carcinoma in situ; 76.7% of invasive cancers were ≤ 20 mm in size, 30.2% were ≤ 10 mm, and 75.3% were node-negative. During the implementation period, incidence increased by 37 and 56% in the old and new federal states, respectively. Incidence rates decreased following the prevalence phase.
The German MSP was successfully implemented. The results of the prevalence phase meet the target values of the European guidelines. Proper functioning of the program is also verified by its effects on breast cancer incidence. To draw reliable conclusions regarding the long-term effects of the program, results from the routine screening rounds have to be awaited.
德国乳腺X线筛查项目(German MSP)是以人群为基础的,针对年龄在50 - 69岁的女性(约1050万)。该项目于2005年启动,并在5年内实施。本文描述了其实施情况、结构和筛查过程,并呈现了患病率阶段初次检查的结果。
每年从邀请中心(邀请、出勤情况)、筛查单位(检查执行情况、结果)和癌症登记处(发病率)收集数据。
2009年,每年所有符合条件的女性中有92%被邀请;符合条件人群的50%参与了筛查。2005 - 2009年期间的总癌症检出率为8.1/1000;相应的召回率为5.9%。检测出的癌症中19.6%为导管原位癌;76.7%的浸润性癌大小≤20 mm,30.2%≤10 mm,75.3%无淋巴结转移。在实施期间,老联邦州和新联邦州的发病率分别上升了37%和56%。患病率阶段之后发病率有所下降。
德国乳腺X线筛查项目成功实施。患病率阶段的结果符合欧洲指南的目标值。该项目对乳腺癌发病率的影响也验证了其运作良好。要得出关于该项目长期效果的可靠结论,还需等待常规筛查轮次的结果。